XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.469
+0.034 (7.75%)
At close: Mar 6, 2026, 4:00 PM EST
0.466
-0.002 (-0.51%)
After-hours: Mar 6, 2026, 7:45 PM EST

XORTX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Jan '22 2021 - 2017
Selling, General & Admin
1.832.192.281.931.22
Upgrade
Research & Development
0.570.182.426.760.68
Upgrade
Amortization of Goodwill & Intangibles
0.030.030.070.020.01
Upgrade
Operating Expenses
2.542.624.969.242.31
Upgrade
Operating Income
-2.54-2.62-4.96-9.24-2.31
Upgrade
Interest Expense
-----0
Upgrade
Interest & Investment Income
0.040.120.250.1-
Upgrade
Currency Exchange Gain (Loss)
-0-0.07-0.01-0-0.01
Upgrade
Other Non Operating Income (Expenses)
-0.15-0.752.551.420.75
Upgrade
EBT Excluding Unusual Items
-2.65-3.31-2.16-7.72-1.58
Upgrade
Asset Writedown
-0----
Upgrade
Pretax Income
-2.66-3.31-2.16-7.72-1.58
Upgrade
Net Income
-2.66-3.31-2.16-7.72-1.58
Upgrade
Net Income to Common
-2.66-3.31-2.16-7.72-1.58
Upgrade
Shares Outstanding (Basic)
53211
Upgrade
Shares Outstanding (Diluted)
53211
Upgrade
Shares Change (YoY)
64.48%45.25%33.91%35.25%47.77%
Upgrade
EPS (Basic)
-0.56-1.15-1.09-5.22-1.44
Upgrade
EPS (Diluted)
-0.56-1.15-1.09-5.22-1.44
Upgrade
Free Cash Flow
-2.77-3.68-6.59-8.19-4.8
Upgrade
Free Cash Flow Per Share
-0.58-1.28-3.32-5.53-4.39
Upgrade
EBITDA
-2.43-2.58-4.88-9.22-2.3
Upgrade
D&A For EBITDA
0.110.040.070.020.01
Upgrade
EBIT
-2.54-2.62-4.96-9.24-2.31
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.